a 5-HT 4 receptor (5-HT 4 R) activation induces procognitive effects. This might be related to stimulation of hippocampal acetylcholine release, which has been shown for 5-HT 4 R agonists in in-vivo models. We investigated the influence of the 5-HT 4 R agonists, prucalopride and BIMU-8, on acetylcholine release in rat hippocampal brain slices. In contrast to the report by Siniscalchi et al., no facilitating effect of 5-HT 4 R agonists on electrically evoked acetylcholine could be shown. The in our hands absence of an effect by 5-HT4R agonists illustrates that an in-vitro evaluation of 5-HT 4 R agonists on hippocampal acetylcholine release is not a straightforward model to study the relationship between hippocampal 5-HT 4 Rs and hippocampal acetylcholine release.
Introduction
Pharmacological studies have shown that 5-HT 4 receptor (5-HT 4 R) activation induces procognitive effects and increases memory and learning [1] [2] [3] [4] . 5-HT 4 R have shown to be present in the hippocampus [5, 6] . The procognitive effects of 5-HT 4 R stimulation might be the result of the induction of long-term potentiation as shown in the amygdala [7] and suggested in the hippocampus [8] , where 5-HT 4 R activation causes a long-lasting increase in excitability of cornus ammonis 1 pyramidal neurons [3, 9, 10] . In contrast, the procognitive effects of 5-HT 4 R agonists might also be related to the increased acetylcholine release, as shown in vivo in the hippocampus [3] and the frontal cortex [11] of conscious freely moving rats. The loss of hippocampal cholinergic markers is indeed one of the major neurochemical deficits in Alzheimer's disease, which correlates well with the loss of cognitive abilities [12] , and actual treatment of patients with Alzheimer's disease is mainly with cholinesterase inhibitors [13] . In vitro, the facilitation of acetylcholine release from guinea pig and rat hippocampal brain slices by 5-HT 4 R activation has been described by Siniscalchi et al. [14] and this study is regularly cited to suggest the presence of presynaptic 5-HT 4 heteroreceptors on hippocampal cholinergic nerve terminals [15, 16] , although no other reports on increased acetylcholine release by 5-HT 4 R agonists in hippocampal brain slices have been published. In view of the report by Siniscalchi et al. [14] , this study investigated the influence of the highly selective 5-HT 4 R agonist prucalopride on acetylcholine release in rat hippocampal brain slices.
Materials and methods
In most experiments, male Wistar rats (200-300 g) were used. To rule out possible species differences due to variations in 5-HT 4 R density, male Dunkin-Hartley guinea pigs (350-500 g) were used in a series of experiments. Animals were housed under controlled conditions of temperature, humidity, and light (12 h light/dark), and received food and water ad libitum. On the day of the experiment, the animals were killed by decapitation, under light CO 2 anesthesia, and the brain was quickly removed to ice-cold modified Krebs' solution of the following composition (mM): NaCl, 124.0; KCl, 3.0; KH 2 PO 4 , 1.25; MgSO 4 , 1.0; CaCl 2 , 2.0; NaHCO 3 , 26.0; ascorbic acid, 0.3; Na 2 ethylenediaminetetra-acetic acid, 0.03; and glucose, 10.0 (pH 7.4) oxygenated with 95% O 2 and 5% CO 2 . In experiments with guinea pig, the composition of the Krebs' solution was as described by Siniscalchi et al. [14] . The hippocampi were dissected from the cooled brain and coronal sections (rat, 350 mm; guinea pig, 400 mm) were cut with a McIlwain tissue chopper (Stoelting, Wood Dale, Illinois, USA) to yield 16 dorsal hippocampal slices per animal. In a limited number of experiments, slices from rat were cut with a Microm HM 650 V (Thermo Fisher Scientific, Waltham, Massachusett, USA) vibratome. To prepare the brain for cutting, the cerebellum and the frontal lobe were removed by a coronal section; the brain was then tilted on the frontal end to remove ventral-lateral areas (20-301 off the horizontal axis). Finally, a medial sagittal cut was performed on the remaining tissue and the ventral lateral areas were glued onto the specimen holder of the vibratome. About eight horizontal 350-mm hippocampal slices were obtained per animal. Slices were loaded with [ 3 H]-choline chloride (10 mCi/ml, 0.1 mM) in 2 ml of Krebs' solution for 45 min at 371C. The slices were rinsed three times and transferred to 200 ml of chambers (four per chamber) in an automated perfusion system (Brandel SF-2518B; Brandel Inc., Gaithersburg, Maryland, USA). Perfusion was done with carbogen-saturated Krebs' solution containing 2 mM of hemicholinium-3 at a flow rate of 1.2 ml/min. After 1 h of perfusion, 3-min samples of the effluent were collected and assayed for tritium content as a measure for [ 3 H]-ACh. Electrical field stimulation through platinum ring electrodes was applied twice at 15 and 45 min after the beginning of the collection period (S 1 , S 2 ); biphasic square wave pulses were delivered by an ES-218 (Brandel Inc.) stimulator at 50 mA, 1 ms, at a frequency of 2 Hz for 2 min (240 pulses). In guinea pig experiments, square wave pulses of alternating polarity were used. Drugs were added 15 min before S 2 . At the end of the experiments, tissues were homogenized by sonication in 0.5 ml of 10% trichloroacetic acid for 30 min and a 100-ml aliquot was used to determine the amount of tritium remaining in the tissue. The tritium content of the sample was assayed by adding a 0.5-ml aliquot of perfusate samples to 2 ml of Ultima Gold scintillation fluid (Perkin Elmer, Waltham, Massachusetts, USA) and measured using liquid scintillation counting (Tri-Carb 2100 TR; Perkin Elmer) for 5 min. Tritium outflow was expressed as fractional release, that is, as a percentage of the total amount of tritium in the tissue at the time of sample collection. The uptake of tritium was determined as the sum of release plus tissue content of radioactivity at the end of the experiment. The release of tritium by electrical field stimulation (stimulation-evoked release S 1 , S 2 ) was calculated by subtracting basal release, measured for 9 min during the immediate prestimulation period, from the release measured for 9 min from the start of the stimulation. The effect of the drugs on field stimulation-evoked tritium outflow was evaluated as the S 2 /S 1 ratio compared with the S 2 /S 1 ratio in control slices without drug addition.
Drugs
The following drugs were used: [ 3 H]-methyl-choline chloride (Perkin Elmer; specific activity 75.7 Ci/mmol), hemicholinium-3 bromide and atropine sulfate (SigmaAldrich, St Louis, Missouri, USA), 2-chloroadenosine (Fluka, Buchs, Switzerland), BIMU-8 (Tocris Cookson, Bristol, UK), prucalopride (Shire-Movetis, Turnhout, Belgium), and tetrodotoxin (Serva, Heidelberg, Germany). All compounds were dissolved and diluted in distilled water.
Statistics
For statistical analysis, GraphPad Prism version 5.0 (GraphPad, San Diego, California, USA) was used to perform one-way analysis of variance followed by the Bonferroni post-hoc test. The data were expressed as means ± standard error of the mean. A P value of less than 0.05 was considered significant in all tests. Figure 1 illustrates the average tritium outflow from rat hippocampal slices obtained in control perfusion experiments. It can be seen that the basal release was stable and that the amount of electrically evoked tritium during the two episodes of electrical stimulation (S 1 and S 2 ) was similar yielding an average S 2 /S 1 ratio of 1.09 ± 0.02 (n = 14). The electrically evoked tritium outflow was completely abolished by 3 mM of tetrodotoxin (n = 4; data not shown) indicating its dependence on action potential propagation through sodium channels. The assay was validated by perfusion of atropine (1 mM) or 2-chloroadenosine (10 mM) 15 min before S 2 . As shown in Fig. 2 , atropine produced a consistent increase (+37%) of the evoked tritium outflow, with the average S 2 /S 1 ratio being 1.48 ± 0.03 (n = 8), whereas perfusion of 2-chloroadenosine produced a consistent decrease (-55%) of the evoked tritium outflow, with the average S 2 /S 1 ratio being 0.49 ± 0.04 (n = 6) versus an average S 2 /S 1 ratio of 1.08 ± 0.03 (n = 10) in control.
Results
However, neither BIMU-8 (2 mM), the 5-HT 4 R agonist that increased the tritium outflow in the study by Siniscalchi et al. [14] by 43%, nor the selective 5-HT 4 R agonist prucalopride (1 mM) facilitated the acetylcholine release from hippocampal brain slices (Fig. 3) . None of the drugs modified the basal tritium outflow.
Prucalopride did not affect the release of acetylcholine at various perfusion times before S 2 (24, 18, 6, 3 min) or at different concentrations (0.01 mM, 0.1 mM; n = 1-2 for each condition). The data set presented above was obtained using a total K + concentration of 4.25 mM and a Ca 2+ concentration of 2 mM in the Krebs solution; the effect of prucalopride has also been assessed in Krebs' solution with high (5.9 mM) concentration of total K + in combination with low (1.4 mM), intermediate (2 mM), or high (2.5 mM) Ca 2+ concentration (n = 1 for each condition). In addition, an experiment has been performed in the absence of Tritium outflow in control slices. Mean ± standard error of the mean (n = 14). Tritium outflow is expressed as a percentage of the tritium retained in the preparations at the time of the sample collection. The bars at S 1 and S 2 indicate the periods of electrical field stimulation. In control experiments, the evoked release of tritium remained constant during the consecutive stimulation periods, giving S 2 /S 1 ratios close to unity.
ethylenediaminetetraacetic acid and ascorbic acid. None of these conditions induced a facilitating effect of prucalopride on acetylcholine release; neither did a different slicing method as similar S 2 /S 1 ratios were obtained with vibratome-made slices (control S 2 /S 1 ratio of 1.11 vs. 1.12 with prucalopride; n = 1).
The absence of an effect by prucalopride was confirmed in hippocampal slices from guinea pig for two stimulation intensities; standard stimulation intensity as used for rat slices (2 Hz, 50 mA, 1 ms) yielded an S 2 /S 1 ratio of 1.07 in control tissues versus 0.99 in tissues treated with prucalopride (n = 1); lower stimulation intensity (0.5 Hz, 50 mA, 1 ms) led to an S 2 /S 1 ratio of 0.93 in controls versus 0.92 with prucalopride present (n = 1).
Discussion
Our study confirmed that reproducible stimulationinduced release of acetylcholine can be obtained from rat hippocampal slices [17] [18] [19] . In accordance with the literature the muscarinic receptor antagonist atropine increased and the mixed A 1 /A 2a adenosine receptor agonist 2-chloroadenosine decreased the evoked tritium outflow resulting from the blockade and stimulation of presynaptic inhibitory control on acetylcholine release through muscarinic and A 1 adenosine receptors, respectively [18, 19] . In contrast with the study by Siniscalchi et al. [14] , however, 5-HT 4 R activation did not modify the electrically evoked tritium outflow from rat or guinea pig hippocampal brain slices in this study. To rule out the possibility that this discrepancy was a result of the slightly different experimental conditions used, the buffer composition, stimulus intensity, agonist, and agonist perfusion time of the study by Siniscalchi et al. [14] were additionally tested but no condition was obtained where 5-HT 4 R agonists showed a facilitating effect on acetylcholine release from the hippocampal brain slices.
Multiple variations in Krebs' solution composition exist in the literature on rat hippocampal [ 3 H]-acetylcholine release [14, [17] [18] [19] [20] . Essentially, total K + concentration ranges from 3 to 6 mM and/or Ca 2+ concentration ranges from 1.2 to 2.5 mM. Adaptation of the K + and Ca 2+ concentration of the Krebs solution did not induce a facilitating effect of prucalopride. The absence of an effect of the 5-HT 4 R agonists in this study was therefore not due to the buffer composition.
Multiple variations in stimulation parameters exist in studies on rat hippocampal [ 3 H]-acetylcholine release [14, 17, 19, 20] . Square wave pulses (monophasic, biphasic or with alternating polarity) are used with typical pulse durations of 1 or 2 ms. Both voltage and current stimulations have been described with frequencies ranging from 0.5 to 3 Hz and stimulation durations from 2 to 4 min. As the intensity of nerve activation could indeed play an important role in the effectiveness of presynaptic receptors modulating transmitter release [21] , ]-acetylcholine in response to the first (S 1 ) and second stimulation (S 2 ) was calculated and compared in the absence and the presence of drug. Mean S 2 /S 1 ratio ± standard error of the mean (n = 6-10). Asterisks show significant differences from control. ***P < 0.001 (one-way analysis of variance; Bonferroni). the lowest stimulation intensity in terms of current and frequency yielding reproducible S 2 /S 1 was used in this study. The low stimulation intensity described by Siniscalchi et al. [14] (30 mA/cm 2 ; at 0.5 Hz) reduced the ratio of evoked release to basal release in the experiments with rat tissue to such an extent that it impeded obtaining reproducible S 2 /S 1 ; as in our experiments too, current stimulation was used, the delivered current should be identical in both setups. From the data by Siniscalchi et al. [14] , however, the stability of the basal release and the ratio of evoked release to basal release cannot be appreciated as no graphical representation of the course of the release experiments was given. In experiments with guinea pig tissue, however, the ratio evoked release to basal release was higher than in experiments with rat tissue, which allowed stimulation at 0.5 Hz whereas preserving reproducible S 2 /S 1 . But still, this did not induce a facilitating effect of 5-HT 4 R agonists.
In the study by Siniscalchi et al. [14] , the 5-HT 4 R agonist BIMU-8 was added to the perfusion medium 3 min before S 2 to minimize the possibility of receptor desensitization. As reducing the perfusion time or concentration of prucalopride before S 2 did not increase the S 2 /S 1 ratio obtained, receptor desensitization can be excluded as possible cause of the absence of an effect of the 5-HT 4 R agonists in this study.
We do not have clear explanation for the discrepancy between our study and this of Siniscalchi et al. [14] . It can still be mentioned that we used Wistar rats and DunkinHartley guinea-pigs, whereas Siniscalchi et al. [14] used Sprague-Dawley rats and a not specified guinea pig strain. As the effects observed by Siniscalchi et al. [14] were observed in both species, strain dependency seems an unlikely explanation. More important, however, could be the procedure used to obtain hippocampal slices. Moreover, it is still unknown whether 5-HT 4 Rs that regulate acetylcholine release within the hippocampus are located on cholinergic nerve terminals, cholinergic cell bodies, or interneurons [16] . The absence of an effect of 5-HT 4 R agonists in our study could be the result of the disruption of essential cholinergic projections. The present data and the failure of 5-HT 4 R agonists to enhance K + -evoked acetylcholine release from hippocampal synaptosomes [14] suggest that 5-HT 4 Rs are not located on the hippocampal cholinergic nerve terminals. A preterminal location of the 5-HT 4 R modulating acetylcholine release could indeed make its functionality prone to the exact slicing procedure used. Unfortunately, Siniscalchi et al. [14] did not specify which specific part of the hippocampus was sliced and which slicing plane was used, which impeded exact mimicking of their slicing conditions.
Conclusion
In rat and guinea pig hippocampal brain slices, no facilitating effect of the 5-HT 4 R agonists, BIMU-8 and prucalopride, on electrically evoked acetylcholine release could be shown in contrast to earlier data. The in-vitro evaluation of 5-HT 4 R agonists on hippocampal acetylcholine release is therefore not a straightforward model to study the relationship between hippocampal 5-HT 4 Rs and hippocampal acetylcholine release.
